An appeals court in Louisiana on Wednesday denied an appeal by a shellfish processing company over a decision that it had to pay for compound cream to treat a worker suffering from pain and found that there was no evidence to show that the cream did not was appropriate.
Bayou Shrimp Processors Inc. and its employee compensation insurer, Bridgefield Employers Insurance Co., appealed against the decision of a State Compensation Judge who approved a current drug for Shelly Delahoussaye and found that it was "permitted without specific restrictions" under state medical guidelines. treatment, according to documents in Bayou Shrimp Processors, Inc. and Bridgefield Employers Insurance Company v. Shelly Delahoussaye, filed with the Louisiana Third Circuit Court of Appeals, in Lake Charles.
Miss. Delahoussaye was "seriously" injured in 201
In 2019, Ms. Delahoussaye's treatment treated painkillers, submitted a formal request for approval of a "Neuro Compound Cream", which he testified was in line with treatment options for pain and has "led to improvements in opiate-free function." A claimant denied the claim. Later that year, a medical director approved the therapy and stated that the cream was in line with the state's medical guidelines.
On appeal, a workers' compensation judge ruled earlier this year that the employer "did not meet its burden of proof through clear and convincing evidence" to overturn the medical director's decision.
The State Board of Appeal upheld the decision and wrote that it found "no manifest error" in the judge's decision "that the petitioners did not support their position with clear and convincing evidence necessary to overturn the medical director's decision."